Cardiac hypertrophy, interstitial fibrosis, and cardiac dysfunction ultimately lead to cardiac failure. Cardiac failure is one of the major causes of heart disease and death in our society. The molecular causes of heart diseases, like many other diseases, remain largely unknown. Recently, large-scale proteomics studies have been undertaken to better understand the underlying mechanisms of molecular causes of heart disease. Many protein alterations have already been identified in the human diseased myocardium. Further experiments on these proteins are ongoing to know their suitability for drug targets, therapeutic proteins, or disease biomarkers. This review deals with a proteomics perspective on human heart failure, and is divided into two parts. The first part provides a glimpse on proteomics technologies used for identification and quantification of proteins related to heart disease. The second part is the main focus of this review and deals with evolving biomarkers and clinical diagnostics, potential future drugs, clinical approaches in managing heart failure, and clinical shortcomings, which are discussed to some detail from the viewpoint of a medical doctor and proteomics scientists.
Keywords: Cardiac proteomics, human disease, two-dimensional gel electrophoresis, mass spectrometry, biomarkers, review
Hypertension to Heart Failure: New Developmental Strategies do not Cross a Clinical and Therapeutic Divide
Current Pharmaceutical Design Selective Peroxisome Proliferator-Activated Receptor-γ Modulation to Reduce Cardiovascular Risk in Patients with Insulin Resistance
Recent Patents on Cardiovascular Drug Discovery (Discontinued) Contextualizing Genetics for Regional Heart Failure Care
Current Cardiology Reviews Carotid Baroreceptor Stimulation: A Promising Approach for the Management of Resistant Hypertension and Heart Failure
Current Vascular Pharmacology CPP-conjugated Anti-apoptotic Peptides as Therapeutic Tools of Ischemiareperfusion Injuries
Current Pharmaceutical Design Anthracycline-Induced Cardiotoxicity
Cardiovascular & Hematological Agents in Medicinal Chemistry The Patented Uses of D-Ribose in Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery (Discontinued) Blockade of Renin Angiotensin System in Heart Failure Post-Myocardial Infarction: What is the Best Therapy?
Recent Patents on Cardiovascular Drug Discovery (Discontinued) Beta-Blocker Therapy for Septic Cardiac Shock: Fiction Or Realism?
Current Drug Therapy Intra - and Intercellular Calcium Handling in Pulmonary Arterial Hypertension
Medicinal Chemistry Endoplasmic Reticulum Stress as a Novel Therapeutic Target in Heart Diseases
Cardiovascular & Hematological Disorders-Drug Targets Developing New Anti-Arrhythmics: Clues from the Molecular Basis of Cardiac Ryanodine Receptor (RyR2) Ca2+-Release Channel Dysfunction
Current Pharmaceutical Design Molecular Mechanisms of Mineralocorticoid Receptor Antagonism by Eplerenone
Mini-Reviews in Medicinal Chemistry Myocardial Tissue Engineering and Heart Muscle Repair
Current Pharmaceutical Biotechnology Modulation of Cardiac and Hepatic Cytochrome P450 Enzymes During Heart Failure
Current Drug Metabolism Repetitive Transient Phosphodiesterase-3 Inhibition Eliminates Non-ischemic Cardiac Remodeling and Failure
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Under Re-organization) Stage B: What is the Evidence for Treatment of Asymptomatic Left Ventricular Dysfunction?
Current Cardiology Reviews Melanocortin-4 Receptor Antagonists as Potential Therapeutics in the Treatment of Cachexia
Current Topics in Medicinal Chemistry Dronedarone: A Safety Comparison to Amiodarone
Current Drug Safety Drug Therapy for Hypertrophic Cardiomypathy: Physiology and Practice
Current Cardiology Reviews